Metabolic phenotype of bladder cancer

Ferlay, 2015, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer, 136, E359, 10.1002/ijc.29210 Griffin, 2004, Metabolic profiles of cancer cells, Nat Rev Cancer, 4, 551, 10.1038/nrc1390 Cheng, 2015, Metabolomics in bladder cancer: a systematic review, Int J Clin Exp Med, 8, 11052 Warburg, 1956, On the origin of cancer cells, Science, 123, 309, 10.1126/science.123.3191.309 Vander Heiden, 2009, Understanding the Warburg effect: the metabolic requirements of cell proliferation, Science, 324, 1029, 10.1126/science.1160809 Macheda, 2005, Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer, J Cell Physiol, 202, 654, 10.1002/jcp.20166 Ramos-Montoya, 2006, Pentose phosphate cycle oxidative and nonoxidative balance: a new vulnerable target for overcoming drug resistance in cancer, Int J Cancer, 119, 2733, 10.1002/ijc.22227 Hatzivassiliou, 2005, ATP citrate lyase inhibition can suppress tumor cell growth, Cancer Cell, 8, 311, 10.1016/j.ccr.2005.09.008 Gatenby, 2006, Acid-mediated tumor invasion: a multidisciplinary study, Cancer Res, 66, 5216, 10.1158/0008-5472.CAN-05-4193 Fischer, 2007, Inhibitory effect of tumor cell-derived lactic acid on human T cells, Blood, 109, 3812, 10.1182/blood-2006-07-035972 Hoskin, 2003, GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON, Br J Cancer, 89, 1290, 10.1038/sj.bjc.6601260 Al Hasawi, 2014, Phosphofructokinase: a mediator of glycolytic flux in cancer progression, Crit Rev Oncol Hematol, 92, 312, 10.1016/j.critrevonc.2014.05.007 Jiang, 2013, Proteomic analysis of bladder cancer by iTRAQ after Bifidobacterium infantis-mediated HSV-TK/GCV suicide gene treatment, Biol Chem, 394, 1333, 10.1515/hsz-2013-0201 Mitchell, 1989, Enzyme studies in human transitional cell carcinoma of the urinary bladder, J Urol, 141, 1234, 10.1016/S0022-5347(17)41228-6 Deshpande, 1991, Tumor enzymes and prognosis in transitional cell carcinoma of the bladder: prediction of risk of progression in patients with superficial disease, J Urol, 146, 1247, 10.1016/S0022-5347(17)38060-6 Conde, 2015, The progression from a lower to a higher invasive stage of bladder cancer is associated with severe alterations in glucose and pyruvate metabolism, Exp Cell Res, 335, 91, 10.1016/j.yexcr.2015.04.007 Dettmer, 2013, Distinct metabolic differences between various human cancer and primary cells, Electrophoresis, 34, 2836 Kim, 2006, HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia, Cell Metab, 3, 177, 10.1016/j.cmet.2006.02.002 Jiang, 2015, LDH-A promotes malignant progression via activation of epithelial-to-mesenchymal transition and conferring stemness in muscle-invasive bladder cancer, Biochem Biophys Res Commun Choi, 2014, Prognostic significance of lactate/proton symporters MCT1, MCT4, and their chaperone CD147 expressions in urothelial carcinoma of the bladder, Urology, 84, 10.1016/j.urology.2014.03.031 Afonso, 2015, Metabolic coupling in urothelial bladder cancer compartments and its correlation to tumour aggressiveness, Cell Cycle Shi, 2015, Overexpression of monocarboxylate anion transporter 1 and 4 in T24-induced cancer-associated fibroblasts regulates the progression of bladder cancer cells in a 3D microfluidic device, Cell Cycle, 14, 3058, 10.1080/15384101.2015.1053666 Liu, 2016, Overexpression of ABCC3 promotes cell proliferation, drug resistance, and aerobic glycolysis and is associated with poor prognosis in urinary bladder cancer patients, Tumour Biol, 10.1007/s13277-015-4703-5 Swietach, 2007, Regulation of tumor pH and the role of carbonic anhydrase 9, Cancer Metastasis Rev, 26, 299, 10.1007/s10555-007-9064-0 Atsumi, 2002, High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers, Cancer Res, 62, 5881 Lea, 2015, Inhibition of growth of bladder cancer cells by 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one in combination with other compounds affecting glucose metabolism, Anticancer Res, 35, 5889 Luo, 2008, Protein expression and amplification of AIB1 in human urothelial carcinoma of the bladder and overexpression of AIB1 is a new independent prognostic marker of patient survival, Int J Cancer, 122, 2554, 10.1002/ijc.23399 Zhang, 2013, Steroid receptor coactivator-3 promotes bladder cancer through upregulation of CXCR4, Asian Pac J Cancer Prev, 14, 3847, 10.7314/APJCP.2013.14.6.3847 Zhao, 2014, Steroid receptor coactivator-3 regulates glucose metabolism in bladder cancer cells through coactivation of hypoxia inducible factor 1α, J Biol Chem, 289, 11219, 10.1074/jbc.M113.535989 Boros, 1997, Oxythiamine and dehydroepiandrosterone inhibit the nonoxidative synthesis of ribose and tumor cell proliferation, Cancer Res, 57, 4242 Langbein, 2006, Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted, Br J Cancer, 94, 578, 10.1038/sj.bjc.6602962 Raïs, 1999, Oxythiamine and dehydroepiandrosterone induce a G1 phase cycle arrest in Ehrlich’s tumor cells through inhibition of the pentose cycle, FEBS Lett, 456, 113, 10.1016/S0014-5793(99)00924-2 Comin-Anduix, 2002, Fermented wheat germ extract inhibits glycolysis/pentose cycle enzymes and induces apoptosis through poly(ADP-ribose) polymerase activation in Jurkat T-cell leukemia tumor cells, J Biol Chem, 277, 46408, 10.1074/jbc.M206150200 Wang, 2015, Zoledronic acid inhibits the pentose phosphate pathway through attenuating the Ras-TAp73-G6PD axis in bladder cancer cells, Mol Med Rep, 12, 4620, 10.3892/mmr.2015.3995 Platt, 2009, Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer, Clin Cancer Res, 15, 6008, 10.1158/1078-0432.CCR-09-0898 Aveyard, 1999, Somatic mutation of PTEN in bladder carcinoma, Br J Cancer, 80, 904, 10.1038/sj.bjc.6690439 Massari, 2015, The route to personalized medicine in bladder cancer: where do we stand?, Target Oncol, 10, 325, 10.1007/s11523-015-0357-x Puzio-Kuter, 2009, Inactivation of p53 and Pten promotes invasive bladder cancer, Genes Dev, 23, 675, 10.1101/gad.1772909 Robey, 2009, Is Akt the “Warburg kinase”? – Akt-energy metabolism interactions and oncogenesis, Semin Cancer Biol, 19, 25, 10.1016/j.semcancer.2008.11.010 Elstrom, 2004, Akt stimulates aerobic glycolysis in cancer cells, Cancer Res, 64, 3892, 10.1158/0008-5472.CAN-03-2904 Buzzai, 2005, The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation, Oncogene, 24, 4165, 10.1038/sj.onc.1208622 Zha, 2011, MTOR upregulation of glycolytic enzymes promotes tumor development, Cell Cycle, 10, 1015, 10.4161/cc.10.7.15063 Sun, 2011, Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth, Proc Natl Acad Sci USA, 108, 4129, 10.1073/pnas.1014769108 Düvel, 2010, Activation of a metabolic gene regulatory network downstream of mTOR complex 1, Mol Cell, 39, 171, 10.1016/j.molcel.2010.06.022 Bartel, 2004, MicroRNAs: genomics, biogenesis, mechanism, and function, Cell, 116, 281, 10.1016/S0092-8674(04)00045-5 Calin, 2006, MicroRNA signatures in human cancers, Nat Rev, 6, 857, 10.1038/nrc1997 Singh, 2011, Regulation of aerobic glycolysis by microRNAs in cancer, Mol Cell Pharmacol, 3, 125 Zabolotneva, 2013, Characteristic patterns of microRNA expression in human bladder cancer, Front Genet, 3, 1 Pignot, 2013, MicroRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer, Int J Cancer, 132, 2479, 10.1002/ijc.27949 Wiklund, 2011, Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer, Int J Cancer, 128, 1327, 10.1002/ijc.25461 Dyrskjøt, 2009, Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro, Cancer Res, 69, 4851, 10.1158/0008-5472.CAN-08-4043 Tao, 2011, MicroRNA-21 modulates cell proliferation and sensitivity to doxorubicin in bladder cancer cells, Oncol Rep, 25, 1721 Yang, 2015, A lentiviral sponge for miRNA-21 diminishes aerobic glycolysis in bladder cancer T24 cells via the PTEN/PI3K/AKT/mTOR axis, Tumour Biol, 36, 383, 10.1007/s13277-014-2617-2 Berg, 2002 Rousset, 1981, Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins, Cancer Res, 41, 1165 Rousset, 1979, Presence and cell growth-related variations of glycogen in human colorectal adenocarcinoma cell lines in culture, Cancer Res, 39, 531 Pelletier, 2012, Glycogen synthesis is induced in hypoxia by the hypoxia-inducible factor and promotes cancer cell survival, Front Oncol, 2, 18, 10.3389/fonc.2012.00018 Pescador, 2010, Hypoxia promotes glycogen accumulation through hypoxia inducible factor (HIF)-mediated induction of glycogen synthase 1, PLoS ONE, 5, e9644, 10.1371/journal.pone.0009644 Shen, 2010, Hypoxia-inducible factor 1-mediated regulation of PPP1R3C promotes glycogen accumulation in human MCF-7 cells under hypoxia, FEBS Lett, 584, 4366, 10.1016/j.febslet.2010.09.040 Rousset, 1984, Growth-related enzymatic control of glycogen metabolism in cultured human tumor cells, Cancer Res, 44, 154 Lee, 2004, Metabolic sensitivity of pancreatic tumour cell apoptosis to glycogen phosphorylase inhibitor treatment, Br J Cancer, 91, 2094, 10.1038/sj.bjc.6602243 Ritterson Lew, 2015, Targeting glycogen metabolism in bladder cancer, Nat Rev Urol, 12, 383, 10.1038/nrurol.2015.111 Lee, 2005, Glucose transporter-1 expression in urothelial papilloma of the bladder, Urol Int, 74, 268, 10.1159/000083561 Chang, 2000, Expression of the human erythrocyte glucose transporter in transitional cell carcinoma of the bladder, Urology, 55, 448, 10.1016/S0090-4295(99)00474-4 Younes, 2001, Glut 1 expression in transitional cell carcinoma of the urinary bladder is associated with poor patient survival, Anticancer Res, 21, 575 Guin, 2014, Role in tumor growth of a glycogen debranching enzyme lost in glycogen storage disease, J Natl Cancer Inst, 106, 10.1093/jnci/dju062 Goldstein, 2010, Molecular analysis of the AGL gene: identification of 25 novel mutations and evidence of genetic heterogeneity in patients with glycogen storage disease type III, Genet Med, 12, 424, 10.1097/GIM.0b013e3181d94eaa Jain, 2012, Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation, Science, 336, 1040, 10.1126/science.1218595 Favaro, 2012, Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells, Cell Metab, 16, 751, 10.1016/j.cmet.2012.10.017 Terashima, 2014, KIAA1199 interacts with glycogen phosphorylase kinase β-subunit (PHKB) to promote glycogen breakdown and cancer cell survival, Oncotarget, 5, 7040, 10.18632/oncotarget.2220 Favaro, 2013, Targeting glycogen metabolism: a novel strategy to inhibit cancer cell growth?, Oncotarget, 4, 3, 10.18632/oncotarget.841 Besiroglu, 2015, Lipid metabolism profiling and bladder cancer, Metabolomics, 5, 154 Putluri, 2011, Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression, Cancer Res, 71, 7376, 10.1158/0008-5472.CAN-11-1154 Jin, 2014, Diagnosis of bladder cancer and prediction of survival by urinary metabolomics, Oncotarget, 5, 1635, 10.18632/oncotarget.1744 Huang, 2011, Bladder cancer determination via two urinary metabolites: a biomarker pattern approach, Mol Cell Proteomics, 10, 10.1074/mcp.M111.007922 Cao, 2012, NMR-based metabolomic analysis of human bladder cancer, Anal Sci, 28, 451, 10.2116/analsci.28.451 Zhang, 2012, NMR-based metabolomics study of canine bladder cancer, Biochim Biophys Acta, 1822, 1807, 10.1016/j.bbadis.2012.08.001 Tripathi, 2013, HR-MAS NMR tissue metabolomic signatures cross-validated by mass spectrometry distinguish bladder cancer from benign disease, J Proteome Res, 12, 3519, 10.1021/pr4004135 Menendez, 2007, Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis, Nat Rev Cancer, 7, 763, 10.1038/nrc2222 Jiang, 2012, Inhibition of fatty-acid synthase suppresses P-AKT and induces apoptosis in bladder cancer, Urology, 80, 10.1016/j.urology.2012.02.046 Zheng, 2015, Downregulation of fatty acid synthase complex suppresses cell migration by targeting phospho-AKT in bladder cancer, Mol Med Rep, 10.3892/mmr.2015.4746 Chen, 2015, Molecular events are associated with resistance to vinblastine in bladder cancer, Cell Mol Biol (Noisy-le-grand), 61, 33 Turyn, 2003, Increased activity of glycerol 3-phosphate dehydrogenase and other lipogenic enzymes in human bladder cancer, Horm Metab Res, 35, 565, 10.1055/s-2003-43500 Wittmann, 2014, Bladder cancer biomarker discovery using global metabolomic profiling of urine, PLoS ONE, 9, e115870, 10.1371/journal.pone.0115870 Lin, 2012, LC-MS-based serum metabolic profiling for genitourinary cancer classification and cancer type-specific biomarker discovery, Proteomics, 12, 2238, 10.1002/pmic.201200016 Bansal, 2013, Low- and high-grade bladder cancer determination via human serum-based metabolomics approach, J Proteome Res, 12, 5839, 10.1021/pr400859w Pasikanti, 2013, Urinary metabotyping of bladder cancer using two-dimensional gas chromatography time-of-flight mass spectrometry, J Proteome Res, 12, 3865, 10.1021/pr4000448 von Rundstedt, 2016, Integrative pathway analysis of metabolic signature in bladder cancer – a linkage to the cancer genome atlas project and prediction of survival, J Urol, 10.1016/j.juro.2016.01.039 Cao, 2007, Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia, Cancer Chemother Pharmacol, 59, 495, 10.1007/s00280-006-0291-9 Liu, 2012, A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo, Mol Cancer Ther, 11, 1672, 10.1158/1535-7163.MCT-12-0131 Pelicano, 2006, Glycolysis inhibition for anticancer treatment, Oncogene, 25, 4633, 10.1038/sj.onc.1209597 Le, 2010, Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression, Proc Natl Acad Sci USA, 107, 2037, 10.1073/pnas.0914433107 Clem, 2008, Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth, Mol Cancer Ther, 7, 110, 10.1158/1535-7163.MCT-07-0482 Schnier, 2003, Inhibition of glycogen phosphorylase (GP) by CP-91,149 induces growth inhibition correlating with brain GP expression, Biochem Biophys Res Commun, 309, 126, 10.1016/S0006-291X(03)01542-0 Kaiser, 2001, The cyclin-dependent kinase (CDK) inhibitor flavopiridol inhibits glycogen phosphorylase, Arch Biochem Biophys, 386, 179, 10.1006/abbi.2000.2220 Liu, 2004, A phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer, Clin Cancer Res, 10, 924, 10.1158/1078-0432.CCR-03-0050 Seront, 2012, Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers, Ann Oncol, 23, 2663, 10.1093/annonc/mds057 Milowsky, 2013, Phase II study of everolimus in metastatic urothelial cancer, BJU Int, 112, 462, 10.1111/j.1464-410X.2012.11720.x